GLP-1 Drugs & the Heart: LEADER, SUSTAIN-6, and the Landmark SELECT Trial

The CVOT Era: Why These Trials Changed Everything

Before 2008, cardiovascular safety of diabetes drugs was assumed rather than proven. The ACCORD and UKPDS controversies, along with the rosiglitazone cardiac signal, prompted the FDA to mandate cardiovascular outcome trials (CVOTs) for all new diabetes therapies. What emerged from this regulatory requirement was far more profound than anyone anticipated: GLP-1 receptor agonists didn't just avoid cardiovascular harm — they actively prevented heart attacks, strokes, and cardiovascular death.

The story begins with liraglutide in 2016 and culminates in the 2023 SELECT trial, which proved that cardiovascular protection from GLP-1 drugs exists entirely independent of glucose control — a paradigm shift that is reshaping cardiology practice worldwide.

LEADER Trial (2016): The Proof of Concept

The LEADER trial enrolled 9,340 patients with type 2 diabetes and high cardiovascular risk across 32 countries. Participants were randomized to liraglutide (Victoza) or placebo on top of standard care and followed for a median of 3.8 years. The primary endpoint was 3-point MACE: composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

The results were striking: liraglutide reduced MACE by 13% compared to placebo (HR 0.87, 95% CI 0.78–0.97, p<0.001 for non-inferiority; p=0.01 for superiority). Drilling into the components, cardiovascular death was reduced by 22% — the most dramatic signal. Non-fatal MI trended toward reduction but did not reach significance alone, and non-fatal stroke showed a modest, non-significant trend.

LEADER established liraglutide as the first GLP-1 receptor agonist to demonstrate superior cardiovascular outcomes, setting the stage for the next generation of trials.

SUSTAIN-6 (2016): Semaglutide's Stroke Signal

Running nearly concurrently with LEADER, the SUSTAIN-6 trial tested subcutaneous semaglutide (0.5mg and 1.0mg weekly) in 3,297 patients with type 2 diabetes at high cardiovascular risk. Despite a shorter follow-up of 2.1 years, the results were striking: a 26% reduction in 3-point MACE (HR 0.74, 95% CI 0.58–0.95, p<0.001 for non-inferiority).

Crucially, the SUSTAIN-6 signal was driven primarily by non-fatal stroke reduction — a 39% reduction (HR 0.61). This robust stroke benefit has made semaglutide particularly compelling for patients with prior cerebrovascular events or high stroke risk. Non-fatal MI was also reduced by 26%. Retinopathy complications were more frequent with semaglutide (a known class effect during rapid glucose normalization), which remains an important monitoring consideration.

PIONEER 6 (2019): Oral Semaglutide Joins the Picture

The development of oral semaglutide (Rybelsus) raised the question of whether the cardiovascular benefit was preserved via oral delivery. PIONEER 6 enrolled 3,183 patients with type 2 diabetes at high cardiovascular risk and tested oral semaglutide 14mg daily versus placebo. While the trial was sized for non-inferiority rather than superiority, the results showed a 21% MACE reduction (HR 0.79, 95% CI 0.57–1.11) — directionally consistent with injectable semaglutide but not powered to achieve statistical superiority.

PIONEER 6 confirmed that oral GLP-1 delivery does not compromise the cardiovascular signal, supporting oral semaglutide as a viable option for patients who prefer to avoid injections while still benefiting from cardioprotection.

SELECT (2023): The Trial That Changed Cardiology

The SELECT trial was the most consequential cardiovascular outcome trial in the GLP-1 era — and arguably one of the most important cardiovascular trials of the past decade. Its design broke from all prior CVOTs in one crucial way: enrolled patients did not have diabetes.

SELECT enrolled 17,604 adults aged 45 or older with a BMI of 27 or higher and established cardiovascular disease (prior MI, stroke, or peripheral arterial disease) but without diabetes at baseline. Participants were randomized to semaglutide 2.4mg subcutaneously weekly (the Wegovy dose) or placebo and followed for a median of 3.3 years.

The primary outcome — 3-point MACE — was reduced by 20% (HR 0.80, 95% CI 0.72–0.90, p<0.001). All three components showed directional benefit: cardiovascular death (HR 0.85), non-fatal MI (HR 0.72), and non-fatal stroke (HR 0.67).

Why SELECT Is a Paradigm Shift

The pivotal question SELECT answered: is the cardiovascular benefit of GLP-1 drugs mediated purely through glucose lowering, or does it reflect a direct effect on the cardiovascular system?

SELECT's answer was unambiguous. In a population where there was no blood glucose to lower (participants were normoglycemic), semaglutide still produced a 20% MACE reduction. The weight difference between groups was approximately 9% — meaningful, but insufficient to explain the full magnitude of the cardiovascular benefit observed within the trial's timeframe.

This proves that GLP-1 receptor agonists possess intrinsic cardioprotective mechanisms operating independently of both glucose control and weight loss. For cardiologists, this fundamentally changes the risk-benefit calculation: patients with established ASCVD and obesity are now candidates for GLP-1 therapy on cardiovascular grounds alone.

Mechanisms: How GLP-1 Drugs Protect the Heart

Understanding why GLP-1 receptor agonists reduce cardiovascular events requires examining the multiple biological pathways through which they operate — many of which act directly on cardiac tissue, independent of metabolic effects.

Direct Cardiac Effects

GLP-1 receptors are expressed on cardiomyocytes — the muscle cells of the heart itself. When activated, these receptors trigger cAMP-mediated signaling pathways that improve left ventricular function, enhance cardiac contractility, and reduce ischemia-reperfusion injury. In animal models of acute MI, GLP-1 receptor activation substantially reduces infarct size when administered at the time of reperfusion — a finding with obvious clinical implications for acute coronary syndrome management.

The STEP-HFpEF trial brought these mechanisms to clinical fruition. In patients with heart failure with preserved ejection fraction (HFpEF) — a phenotype for which treatment options have historically been limited — semaglutide 2.4mg weekly produced significant improvements in 6-minute walk test distance, KCCQ quality-of-life scores, body weight, and CRP levels compared to placebo. Notably, these patients did not have type 2 diabetes, reinforcing the direct cardiac mechanism hypothesis.

Anti-Inflammatory Pathways

Atherosclerosis is fundamentally an inflammatory disease. GLP-1 receptor agonists suppress multiple pro-inflammatory mediators: C-reactive protein (CRP), interleukin-6 (IL-6), and NF-κB signaling — the master transcription factor governing inflammatory gene expression. In SELECT, CRP fell significantly in the semaglutide group, and pre-specified analyses suggested that anti-inflammatory effects contributed meaningfully to the cardiovascular benefit beyond what weight loss alone could explain.

Macrophage polarization toward an anti-inflammatory M2 phenotype, reduced foam cell formation, and decreased oxidized LDL uptake in atherosclerotic plaques have all been demonstrated in preclinical models. These effects may translate to coronary plaque stabilization — converting vulnerable, rupture-prone plaques into more stable, fibrotic lesions less likely to cause acute MI.

Endothelial Function and Blood Pressure

The vascular endothelium — the single-cell layer lining every blood vessel — is a primary target of GLP-1 activity. GLP-1 receptor activation stimulates eNOS (endothelial nitric oxide synthase) upregulation, increasing nitric oxide (NO) production. Nitric oxide is the body's master vasodilator: it relaxes smooth muscle, reduces vascular resistance, and importantly, inhibits platelet aggregation and leukocyte adhesion — all processes central to thrombosis and atherosclerosis progression.

The clinical result is a consistent, modest blood pressure reduction of 3–5 mmHg systolic across GLP-1 trials. While this magnitude seems modest, population studies show that even a 3 mmHg systolic reduction translates to a 20–25% lower risk of stroke and a 15–20% lower risk of heart disease at population scale. Combined with direct mechanisms, this BP effect contributes meaningfully to the observed MACE reductions.

Lipid Effects

GLP-1 receptor agonists produce modest but consistent improvements in the lipid panel. Triglycerides fall meaningfully — by 10–20% in many trials — partly due to reduced hepatic VLDL production and partly through delayed gastric emptying reducing postprandial lipid absorption. LDL cholesterol shows a modest reduction (~5%) that is unlikely to be the primary cardiovascular mechanism but adds to the aggregate risk-factor benefit.

HDL cholesterol tends to increase modestly. Perhaps more importantly, GLP-1 drugs appear to improve LDL particle quality — shifting toward larger, less atherogenic particles — an effect not fully captured by standard lipid panels but measurable with advanced lipoprotein testing.

Weight Loss: Necessary but Not Sufficient

It would be tempting to attribute all cardiovascular benefit to weight loss — and weight loss certainly contributes. Obesity independently drives hypertension, dyslipidemia, inflammation, sleep apnea, and left ventricular hypertrophy. Losing 10–15% of body weight meaningfully reduces all of these.

But SELECT dismantled the "it's just weight loss" argument. The trial's weight differential between semaglutide and placebo was approximately 9% — and yet cardiovascular events diverged from early in the follow-up period, well before maximal weight loss was achieved. Mediation analyses estimated that weight loss alone accounted for less than half of the observed cardiovascular benefit. The remainder reflects the direct vascular, anti-inflammatory, and cardiac mechanisms described above.

This is a critical conceptual point: GLP-1 drugs are not merely sophisticated weight-loss medications that secondarily improve heart health. They are pleiotropic cardiovascular drugs that also cause substantial weight loss — a distinction that matters enormously for prescribing rationale and patient counseling.

Heart Failure, CKD, and Emerging Indications

The cardiovascular story of GLP-1 receptor agonists now extends well beyond MACE prevention into heart failure and chronic kidney disease — two conditions that frequently co-occur with obesity and ASCVD.

STEP-HFpEF: A New Hope for the Most Common Heart Failure

Heart failure with preserved ejection fraction (HFpEF) — characterized by a stiff, non-relaxing left ventricle — affects over half of all heart failure patients and has historically lacked effective disease-modifying treatments. HFpEF disproportionately affects obese, hypertensive women and is strongly inflammatory in pathophysiology.

STEP-HFpEF enrolled patients with HFpEF (EF ≥45%), obesity, and NYHA class II–III symptoms but without type 2 diabetes. Semaglutide 2.4mg weekly versus placebo over 52 weeks produced a co-primary endpoint of improvement in both KCCQ Clinical Summary Score (quality of life) and 6-minute walk test distance — both reached statistical significance. Secondary endpoints including weight, CRP, and NT-proBNP trended favorably.

The implication: GLP-1 receptor agonists may emerge as a standard-of-care component for HFpEF management, an indication previously lacking effective pharmacotherapy.

FLOW Trial: Kidney Protection

The FLOW trial examined semaglutide in patients with type 2 diabetes and chronic kidney disease (CKD). It was stopped early for efficacy — semaglutide significantly reduced the composite kidney endpoint (40% eGFR decline, kidney failure, or renal death) and cardiovascular events. The kidney-protective effects likely reflect reduced glomerular hyperfiltration, lower proteinuria, and anti-inflammatory effects on the glomerulus.

This trial completes a picture of GLP-1 receptor agonists as a class with cardio-renal benefits extending across the organ system — not just a metabolic drug.

SURPASS-CVOT: The Tirzepatide Question

Tirzepatide (Mounjaro/Zepbound) — a dual GIP/GLP-1 receptor agonist — produces greater weight loss (up to 22.5% in SURMOUNT-1) and stronger metabolic effects than GLP-1 mono-agonists. The SURPASS-CVOT trial (~13,000 patients with T2D and high CV risk) is ongoing and hypothesizes cardiovascular superiority over dulaglutide. Results are anticipated within 1–2 years and will determine whether tirzepatide's superior metabolic potency translates to superior cardiovascular outcomes.

Important Caveats and Monitoring Considerations

While the cardiovascular benefit profile of GLP-1 receptor agonists is compelling, several clinical considerations deserve attention in cardiac patients specifically.

Heart Rate Elevation

A consistent finding across GLP-1 CVOT trials is a modest increase in resting heart rate — approximately 2–3 beats per minute with liraglutide and semaglutide. This effect is likely mediated by sympathetic nervous system activation and direct GLP-1 receptor effects on the sinoatrial node. For most patients, a 2–3 bpm increase is clinically trivial. However, in patients with pre-existing tachycardia, paroxysmal supraventricular tachycardia, or inappropriate sinus tachycardia, this warrants monitoring and individualized risk assessment.

Notably, the heart rate elevation did not attenuate the net cardiovascular benefit in any CVOT — the cardioprotective mechanisms outweigh this modest chronotropic effect.

HFrEF Caution

An important distinction: while GLP-1 receptor agonists benefit HFpEF patients, heart failure with reduced ejection fraction (HFrEF) presents a different picture. The LIVE trial (liraglutide in HFrEF) showed no benefit and some signal for harm. Current guidance recommends caution or avoidance in severe HFrEF (EF <35%), pending further data. This is a meaningful clinical carve-out that cardiologists must recognize when evaluating GLP-1 prescribing in heart failure patients.

Nausea and Dehydration Risk

Nausea, vomiting, and decreased appetite are the most common adverse effects of GLP-1 receptor agonists, particularly during dose escalation. In cardiac patients on loop diuretics or in those with marginal renal function, the associated fluid and electrolyte shifts deserve monitoring. Practical approach: start at the lowest available dose, titrate at the slowest approved schedule, counsel patients to maintain hydration, and check electrolytes and renal function at 4–6 weeks post-initiation.

Retinopathy in Rapid Glucose Normalization

SUSTAIN-6 reported a higher rate of retinopathy complications in the semaglutide group — a known phenomenon of rapid glucose normalization in patients with pre-existing retinopathy. This does not represent a class-wide liability but is a monitoring consideration for patients with T2D and established diabetic retinopathy initiating high-dose or rapidly titrated GLP-1 therapy.

The Bottom Line: GLP-1 Drugs as Cardioprotective Therapy

The cardiovascular evidence base for GLP-1 receptor agonists is now among the most robust in modern pharmacology. Across multiple large, well-designed randomized controlled trials enrolling tens of thousands of patients, these drugs consistently reduce the risk of heart attack, stroke, and cardiovascular death — in patients with diabetes, and now proven in patients without diabetes as well.

The SELECT trial represents the capstone of this evidence arc. By demonstrating a 20% MACE reduction in 17,604 non-diabetic obese patients with established cardiovascular disease, it proved that GLP-1 receptor agonists are fundamentally cardioprotective drugs — not merely glucose-lowering agents that happen to improve heart outcomes. The mechanisms are multiple, operating simultaneously across inflammation, endothelial function, direct cardiac biology, blood pressure, and lipid metabolism.

For patients navigating cardiovascular risk, the conversation has changed. For clinicians, the evidence now supports integrating GLP-1 receptor agonists as active cardiovascular risk-reduction therapy — not simply as adjuncts to glucose management. The FDA has recognized this with the 2024 approval of Wegovy for CV event reduction, and the ACC/AHA guidelines now formally endorse the class for patients with T2D and established ASCVD.

The era of GLP-1 drugs as cardiovascular therapy has arrived — and the trial data suggests we are still in the early chapters of understanding the full scope of their benefit.